BRANDL TALOS advises Graph Therapeutics on USD 3.1 million pre-seed financing round

Press release • Venture Capital & Start Ups from Stephan Strass, Lara Präthaler

Graph Therapeutics, a next-generation techbio company, has successfully closed a USD 3.1 million pre-seed financing round. The round is led by Squareone and Merantix Capital, with participation from NAVEC Investment Management and strategic angel investors such as the Atomico Angel Program.

Graph Therapeutics develops an AI-powered platform to bring the precision medicine paradigm to inflammation and immunology (I&I) drug discovery.

Their platform combines complex primary disease models with advanced machine learning to bridge the gap between pre-clinical models and clinical applications. “The complexity of inflammatory and immunological diseases demands a fundamentally different approach to drug discovery. Graph Therapeutics represents what we see as ‘Techbio 3.0’,” explains Dr. Gregory Vladimer, CEO and co-founder of Graph Therapeutics.

» I’m greatly appreciative of BRANDL TALOS’s expert and reliable support in organizing this financing round. I look forward to many further projects with them as we build Graph. «

Dr. Gregory Vladimer, CEO and co-founder of Graph Therapeutics

BRANDL TALOS consisted of Stephan Strass and Lara Präthaler. Squareone was advised by Schönherr (Thomas Kulnigg and Clemens Pretscher), NAVEC was represented by Herbst Kinsky (Philipp Kinsky) and the Atomico Angel Program was advised by Fladgate (Ellie Green).

The team

Stephan Strass

Array
(
    [0] => WP_Term Object
        (
            [term_id] => 5
            [name] => Attorney at Law
            [slug] => attorney-at-law
            [term_group] => 0
            [term_taxonomy_id] => 5
            [taxonomy] => category
            [description] => 
            [parent] => 0
            [count] => 16
            [filter] => raw
        )

    [1] => WP_Term Object
        (
            [term_id] => 4
            [name] => Partner
            [slug] => partner
            [term_group] => 0
            [term_taxonomy_id] => 4
            [taxonomy] => category
            [description] => Partner
            [parent] => 0
            [count] => 11
            [filter] => raw
        )

)

Partner / Venture Capital & Start Ups, Corporate Law & Transactions, BioTech & Lifescience

Stephan advises innovative start-ups, institutional and strategic investors and other companies on acquisitions, financing rounds, joint ventures and exit transactions with a focus on highly regulated industries such as life sciences, biotech and leisure & entertainment. He further specializes in commercial transactions in the life science and biotech sector, including university spin-offs, strategic collaborations, patent and technology license agreements and IP purchase transactions.

He has co-authored commentaries on the EU Merger Act and the Investment Fund Act, and is the author of many academic publications.

University of Vienna, Faculty of Law (Mag. iur. 2015)
Harvard Law School, Master of Laws (LL.M. 2019)

Lara Präthaler

Array
(
    [0] => WP_Term Object
        (
            [term_id] => 21
            [name] => Associate
            [slug] => associate
            [term_group] => 0
            [term_taxonomy_id] => 21
            [taxonomy] => category
            [description] => 
            [parent] => 0
            [count] => 21
            [filter] => raw
        )

)

Associate / Corporate Law & Transactions

Lara is part of our team since 2023.

University of Vienna (Magistra iuris 2022)

Latest insights into
Venture Capital & Start Ups

BRANDL TALOS advises VitreaLab on USD 11m Series A financing round

Press release • Venture Capital & Start Ups from Adrian Zuschmann, Markus Reinfeld

BRANDL TALOS has advised Vitrealab in connection with a USD 11m Series A financing round.

BRANDL TALOS advised Resonate Bio on spin-off from the University of Vienna

Press release • Venture Capital & Start Ups from Stephan Strass

BRANDL TALOS advised biotech company Resonate Bio on the spin-off from the University of Vienna.

BRANDL TALOS advises Smedvig Ventures on Series A financing of chatlyn

Press release • Venture Capital & Start Ups from Roman Rericha, Adrian Zuschmann

BRANDL TALOS has advised lead investor Smedvig Ventures on the EUR 8 million Series A financing round of AI start-up chatlyn.